First biosimilar approved for macular degeneration, other eye conditions

The first biosimilar to Lucentis (ranibizumab injection) has been approved for the treatment of neovascular (wet) age-related macular degeneration and other eye diseases and conditions, the U.S. Food and Drug Administration announced Friday. The approval of the biosimilar, Byooviz (ranibizumab-nuna), is also indicated to treat macular edema after retinal vein occlusion and myopic choroidal neovascularization. […]

Continue Reading

National task force recommends removing race from kidney function equation

A national task force announced Thursday that it is recommending the immediate implementation of a new diagnostic equation for measuring kidney function, which advocates say will promote health equity and increase access to transplantation for Black patients. The recommendation is supported by ongoing research from clinical researchers in the Perelman School of Medicine at the […]

Continue Reading